We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2024 results on Nov. 6, after market close. The ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Gilead Sciences to post earnings of $1.66 ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

Creative Financial Designs Inc. ADV boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.4% during the third quarter, HoldingsChannel.com reports. The institutional investor ...

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

The HIV Community Scholars, supported by Gilead Sciences, are invited to attend APCS 2024 to present their innovative ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...

The Supreme Court of California is gearing up to decide an important question for the future of product liability law: Do drug manufacturers have ...

Expanded agreement includes development of additional transgenic mouse technologies and performance of additional therapeutic antibody research programs FOSTER CITY, CA / ACCESSWIRE / October 31, 2024 ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...